866-997-4948(US-Canada Toll Free)

Chemotherapy Induced Peripheral Neuropathy-Pipeline Review, H2 2019

Published By :

Global Markets Direct

Published Date : Nov 2019

Category :

Pharmaceutical

No. of Pages : 151 Pages

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2019, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 4, 20 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Peripheral Neuropathy - Overview
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development
Achelios Therapeutics Inc
Apexian Pharmaceuticals Inc
Aphios Corp
Aptinyx Inc
Asahi Kasei Pharma Corp
Celgene Corp
DermaXon LLC
Disarm Therapeutics Inc
Emerald Bioscience Inc
Exodos Life Sciences Limited Partnership
Immune Pharmaceuticals Inc
Insys Therapeutics Inc
KannaLife Sciences Inc
Kineta Inc
Kyorin Pharmaceutical Co Ltd
MAKScientific LLC
Metys Pharmaceuticals AG
Mundipharma International Ltd
NeurExo Sciences LLC
Osmol Therapeutucs Inc
PeriphaGen Inc
PharmatrophiX Inc
PledPharma AB
Sensei Biotherapeutics Inc
Sonnet BioTherapeutics Inc
Sova Pharmaceuticals Inc
Stealth BioTherapeutics Corp
Trevena Inc
WEX Pharmaceuticals Inc
Winsantor Inc
YD Life Science Co
Chemotherapy Induced Peripheral Neuropathy - Drug Profiles
(amitriptyline + ketamine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-1083 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-1710 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APH-1503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-2009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-3330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atexakin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BR-297 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Chemotherapy Induced Peripheral Neuropathy and Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DX-0332 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibudilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KCP-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketoprofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KLS-13019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-11A31BHS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MR-309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-2111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRX-2922 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAN-811 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGN-503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pirenzepine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-095 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ricolinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBT-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block Nav 1.8 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SARM1 for Neurology and Glaucoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SV-250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tetrodotoxin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
thrombomodulin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRV-045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YD-308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products
Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones
Featured News & Press Releases
Oct 22, 2019: Disarm Therapeutics reports preclinical data demonstrating small molecule SARM1 inhibitors preserve both axonal structure and function in vitro and in vivo
Sep 04, 2019: Disarm Therapeutics announces first subject enrolled in EPIPHANY natural history study of chemotherapy-induced peripheral neuropathy (CIPN)
Jun 27, 2019: Kannalife to present breakthrough CIPN study findings on the comparison of KLS-13019 to CBD at 29th Annual International Cannabinoid Research Society Conference
May 21, 2019: Kannalife publishes new research on chemotherapy-induced peripheral neuropathy
Jan 17, 2019: PledPharma presents PledOx's phase III program at the Gastrointestinal (GI) Cancers Symposium
Dec 26, 2018: Solasia initiates phase III program for PledOx in Japan
Sep 28, 2018: Study drug for the PledOx global phase III program delivered
Jun 13, 2018: Japanese Medical Agency (PMDA) supports the expansion of the Phase III program for PledOx to include Japanese patients
Apr 16, 2018: Apexian Pharmaceuticals to present two poster sessions at AACR meeting in Chicago - April 14-18, 2018
Feb 08, 2018: Delayed delivery of study drug for the PledOx phase III program - top-line results still expected during 2020, in line with previous communication
Nov 17, 2017: PledPharmas Phase IIb study with PledOx (PLIANT) published in Acta Oncologica
Nov 16, 2017: PledPharma initiates Phase III studies with PledOx before year end 2017
Sep 27, 2017: National Cancer Institute selects Apexian Pharmaceuticals to participate in the Small Business Innovation Research (SBIR) Initiative program
Aug 24, 2017: PledPharma establishes a Scientific Advisory Board for the continued clinical development of PledOx
Aug 02, 2017: Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Universities/Institutes, H2 2019
Table 5: Products under Development by Companies, H2 2019
Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 7: Products under Development by Universities/Institutes, H2 2019
Table 8: Number of Products by Stage and Target, H2 2019
Table 9: Number of Products by Stage and Mechanism of Action, H2 2019
Table 10: Number of Products by Stage and Route of Administration, H2 2019
Table 11: Number of Products by Stage and Molecule Type, H2 2019
Table 12: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2019
Table 13: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Apexian Pharmaceuticals Inc, H2 2019
Table 14: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aphios Corp, H2 2019
Table 15: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aptinyx Inc, H2 2019
Table 16: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Asahi Kasei Pharma Corp, H2 2019
Table 17: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Celgene Corp, H2 2019
Table 18: Chemotherapy Induced Peripheral Neuropathy - Pipeline by DermaXon LLC, H2 2019
Table 19: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Disarm Therapeutics Inc, H2 2019
Table 20: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Emerald Bioscience Inc, H2 2019
Table 21: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Exodos Life Sciences Limited Partnership, H2 2019
Table 22: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H2 2019
Table 23: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Insys Therapeutics Inc, H2 2019
Table 24: Chemotherapy Induced Peripheral Neuropathy - Pipeline by KannaLife Sciences Inc, H2 2019
Table 25: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kineta Inc, H2 2019
Table 26: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2019
Table 27: Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific LLC, H2 2019
Table 28: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Metys Pharmaceuticals AG, H2 2019
Table 29: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mundipharma International Ltd, H2 2019
Table 30: Chemotherapy Induced Peripheral Neuropathy - Pipeline by NeurExo Sciences LLC, H2 2019
Table 31: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Osmol Therapeutucs Inc, H2 2019
Table 32: Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen Inc, H2 2019
Table 33: Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX Inc, H2 2019
Table 34: Chemotherapy Induced Peripheral Neuropathy - Pipeline by PledPharma AB, H2 2019
Table 35: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sensei Biotherapeutics Inc, H2 2019
Table 36: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sonnet BioTherapeutics Inc, H2 2019
Table 37: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sova Pharmaceuticals Inc, H2 2019
Table 38: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Stealth BioTherapeutics Corp, H2 2019
Table 39: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Trevena Inc, H2 2019
Table 40: Chemotherapy Induced Peripheral Neuropathy - Pipeline by WEX Pharmaceuticals Inc, H2 2019
Table 41: Chemotherapy Induced Peripheral Neuropathy - Pipeline by Winsantor Inc, H2 2019
Table 42: Chemotherapy Induced Peripheral Neuropathy - Pipeline by YD Life Science Co, H2 2019
Table 43: Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2019
Table 44: Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 45: Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Molecule Types, H2 2019

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *